Diabetes Market Analysis and Reports | USA Conference Series

Market Analysis - Diabetes 2017

INTRODUCTION:

With the rapid change of lifestyle and climate, day by day diabetes is getting increased among the peoples. The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men than women, but there are more women with diabetes than men. The urban population in developing countries is projected to double between 2000 and 2030. Therefore, the purpose of organising the Diabetes 2017 conference in Charlotte is to reunite the people on a global platform and make them raise hands against diabetes.         
 
Why Charlotte:
 
Charlotte is the largest city in the state North Carolina and is also the second largest city in south-eastern United States. It is the third major fastest growing city in Unites States with an estimated population of 809,958 in 2014 according to some bureau. Most importantly, it's a city setting the pace for financial advancement in the Southeast. It has 325 Fortune 500 organizations, more than 300 worldwide firms and a managing an account focus second just to New York's in size. Charlotte is also home to a number of universities and colleges. North Carolinians are progressively feeling the impacts of diabetes as a huge number of individuals suffering from this disorder and many more undiagnosed. It is estimated that one out of every three children born after 2000 getting affected by diabetes. In the Charlotte metro area, approximately 170,000 people have diabetes. Charlotte is a place with many countenances. Most importantly, it's a city setting the pace for financial advancement in the Southeast. It has 325 Fortune 500 organizations, more than 300 worldwide firms and a managing an account focus second just to New York's in size.
 
Conference Highlights:
 
  • Diabetes Pathophysiology
  • Diabetes and Dermatology
  • Diabetes and Reproduction
  • Advanced Treatments for Diabetes
  • Diabetes and Endocrinology
  • Genetics of Diabetes
  • Paediatric Diabetes
  • Diabetes and Immunology
  • Diabetic Coma
  • Gestational Diabetes
  • Diabetes and Urology
  • Diabetes and its Consequences
  • Diabetes: Nutrition and Myths
  • Diabetes: Case Study and Research
  • Business Analysis
Why to attend???
 
Diabetes is one of the most life threatening disorders if not addressed correctly, may lead to health complications such as kidney failure, blindness or amputation. This conference aimed to explore the knowledge and attitude of people with diabetes mellitus. Day-to-day the prevalence of the disorder is increasing and vast numbers of individuals are unaware of being diagnosed. Greater amount of world population in near future are going to be the victims of this life threatening disorder. According to some analysis it will be increased from 8.9% in 2016 to 10.4% of global adults by 2040. The graph shown below is indicating about the prevalence of the disease and number of people getting affected.   
 
 
Target Audience:
  • Endocrinologists
  • Doctors
  • Physicians
  • Researchers
  • Scientists
  • Diabetes Societies and Associations
  • Business Professionals
  • Academic Professionals
  • Students

Global scenario on Diabetes

World Scenario: According to the survey in 2015-2016, the following results are estimated:
  • One in 11 adults has diabetes (415 million) in 2016.
  • One adult in ten will have diabetes (642 million) by 2040.
  • One in seven births is affected by gestational diabetes.

The above graph is representing the status of the diabetes among the population of 10 different countries in the year 2015-2016 (in millions), ages 20 to 79.
 
The above graph is representing the world diabetes cases by 2035.
 
USA:
 
Half of the US adults currently have diabetes or pre-diabetes, a new study revealed. The total of 29.1million people or 9.3% of the population have diabetes, among them 21.0 million are diagnosed and 8.1million are undiagnosed (27.8% of people with diabetes are undiagnosed).
 
Global market and analysis
 
Worldwide yearly diabetes-related wellbeing consumption is required to add up to US$678Billions, which is assessed to achieve US$800.8Billions. At present, 12% of today's human services use can be identified with the treatment of individuals with diabetes, and 34% of today's worldwide spending on diabetes can be tended to by diabetes application administrations and items. 
 
Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. Orally administered anti-diabetic drugs were leading category of drugs in 2014 and showed a rate of growth of at around 6.3% from the total global sales. The total sales for insulin products also increased.
 
The anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetes drugs. The product revenue in bulk comes from the-test strips, insulin and anti-diabetic drugs – which will remain the largest sources of product revenues over the next ten years. 
 
Anti-diabetic drugs
 
Global industry, Market, R&D and sales forecasts 2016-2026.
 
  • Anti-diabetic drug revenues to 2026 at overall world level, for 9 therapeutic submarkets and 31 products – assess outlooks for production, marketing and sales.
  • Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for demand and revenue potentials.
  • Prospects for established competitors, rising companies and new entrants – explore portfolios, opinions, results, strategies, technologies and outlooks for success.
  • Review of R&D pipelines – examine progress in research and development, finding technological and medical prospects.
  • Analysis of what stimulates and restrains that industry and market – gauge challenges and strengths, helping you compete, gain advantages and succeed.
Top Companies for Diabetes research
 
  • Eli Lilly
  • Novo Nordisk
  • Merck & Co
  • Sanofi
  • Takeda
  • AstraZeneca
  • Johnson &Johnson
  • Novartis
  • Becton, Dickson and Company
  • Business and Economics of Diabetes
The many medical and engineering dimensions to diabetes technology are matched by an equal number of business, economic, insurance coverage and reimbursement problems that must be solved in order for devices manufacturers to develop and provide these technologies for people with diabetes. Good decisions are necessary to develop diabetes technology, but good business decisions are also necessary for this process to succeed.
 
Top Universities under Diabetic Research
 
Following are the Top Universities which are dealing with Diabetic Research
 
  • Harvard University (Cambridge, MA, USA),
  • Massachusetts Institute of Technology (MIT),
  • Columbia University (New York, NY, USA)
  • Oxford University (Oxford, UK)
  • Yale University (New Haven, CT, USA)
  • McMaster University (Hamilton, ON, Canada)
  • University of Basel (Basel, Switzerland)
  • University of Strasbourg (Strasbourg, France)
  • University of Bonn (Bonn, Germany)
  • KU Leuven (Catholic University of Louvain)
  • Swiss Federal Institute of Technology in Lausanne (Lausanne, Switzerland)
  • University of California at Santa Barbara (Santa Barbara, CA, USA)
  • Free University of Amsterdam (VU Amsterdam).
  • Texas A&M University
  • Top Hospitals researching on Diabetes
Following are the Top Hospitals and Research Clinic which are dealing with Diabetic Research
 
  • Mayo clinic (Rochester, MN),
  • Massachusetts General Hospital (Boston, MA)
  • Cleveland Clinic (Cleveland, OH)
  • Johns Hopkins Hospital (Baltimore, MD)
  • USCF Medical Centre (San Francisco, CA)
  • Bassetlaw Hospital – Workshop, Nottinghamshire (UK)
  • Addenbrooke’s Hospital – Cambridge, Barnet General Hospital (UK)
  • Cygnet Hospital Beckton (UK)
  • Wooridul Spine Hospital-Seoul (South Korea)
  • Fortis Memorial Research Institute (India)
  • Gleneagles Medical Centre (Tanglin, Singapore)